Uniferon® approved in UK (replaces Leodex®)
May 18, 2006
Uniferon® has been approved by the Veterinary Medicines Directorate in the United Kingdom (UK) and replaces Leodex®. Uniferon® is Pharmacosmos' veterinary Iron Dextran compound for injection and the worldwide leading injectable Iron Dextran solution for prevention of iron deficiency anemia in piglets.
Leodex® in the UK
Since 1992, Pharmacosmos has supplied the active pharmaceutical ingredient (API) in Leodex® veterinary Iron Dextran solution for injection. Leodex® has been marketed by Leo Laboratories Ltd., a UK subsidiary of Danish-based pharmaceutical company Leo Pharma A/S.
As a natural extension of Pharmacosmos' commitment the UK customers, Pharmacosmos is pleased to announce that the company agreed to acquire Leo Laboratories Ltd.'s marketing authorization of Leodex® earlier in 2006.
Uniferon® replaces Leodex®
As an important part of the procedure of acquiring the marketing authorization of Leodex®, Pharmacosmos has decided to let Uniferon® replace Leodex® as product name. This will allow UK customers to benefit from the strong awareness of the documented positive effects of Uniferon®. Today, Uniferon® has been approved by the UK Veterinary Medicines Directorate.
About Uniferon®
Injection of Uniferon® provides high 200 mg iron per ml for treatment and is an efficient method to prevent iron deficiency anemia. Ensuring healthy and vigorous growth in piglets, Uniferon® has been approved in all major countries including the United States (US).
Please read more information about Uniferon®.